Related Experiment Videos
ACH-126443 Achillion/Yale University
1Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri, Kansas City, 5005 Rockhill Road, Kansas City, MO 64110, USA.
Current Opinion in Investigational Drugs (London, England : 2000)
|December 13, 2002
Summary
Achillion is developing ACH-126443, a nucleoside analog and reverse transcriptase inhibitor, for HIV and hepatitis B virus (HBV) infections. Phase II clinical trials for chronic HBV were underway in 2002.
Area of Science:
- Virology
- Hepatology
- Infectious Diseases
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Antiviral therapies are crucial for managing chronic HBV.
- Nucleoside analogs targeting viral reverse transcriptase are a key therapeutic strategy.
Purpose of the Study:
- To evaluate the safety and efficacy of ACH-126443 (beta-L-Fd4C) in patients with chronic HBV infection.
- To advance the development of a novel reverse transcriptase inhibitor for viral infections.
Main Methods:
- ACH-126443, a nucleoside analog, was developed as a reverse transcriptase (RT) inhibitor.
- Clinical development included Phase II trials for chronic HBV infection.
- Studies were ongoing and expanded in 2002.
Main Results:
- ACH-126443 demonstrated potential as a treatment for HBV infection.
- The compound progressed into Phase II clinical evaluation.
- Further clinical studies were planned to assess its efficacy.
Conclusions:
- ACH-126443 represents a promising therapeutic candidate for chronic HBV.
- The ongoing clinical trials aim to establish its role in antiviral treatment regimens.
- Further research is warranted to fully elucidate its therapeutic potential.